Act Earlier on Trial Signals Across Clinical Programs
Clinical development teams generatecontinuous trial signals, but acting on them within workflows remainsconstrained.
Agentic AI for clinical developmentenables supervised execution under governance, helping teams intervene earlierand improve consistency across development programs.
A Day in
the Life of a Clinical Development Director
You are reviewing interim data acrossmultiple studies - balancing protocol design decisions, evolving endpoints, andincreasing data complexity from diverse sources. Analysis cycles take weeks,while regulatory timelines and internal milestones remain fixed.
Your biostatistics teams arestretched, and meaningful signals often emerge later than they should, limitingthe ability to adapt the study in time.
The challenge is not access to data.It is acting on it early enough to influence outcomes.
The Pressures Clinical Development Leaders Face Every Day
.jpeg)
Industry Reality
Protocol complexity has increased significantly over the past decade
Diverse data sources add analysis burden without increasing capacity
Higher complexity correlates with 30%+ longer study durations
Why Maxis AI Is Built for Clinical Development
Maxis AI delivers a supervised execution layer—an AI Workforce embedded within clinical workflows.
It continuously analyzes protocol design, interim data, and execution signals, while executing defined workflows under governance.
Unlike analytics tools, Maxis AI ensures insights translate into timely, controlled actions that improve development outcomes.
From Pain to Outcome: How Maxis AI Works for You
| Pain Point | AI Capability | Outcome |
|---|---|---|
| Overly complex protocols with redundant endpoints driving amendments and participant burden | AI Workforce analyzes historical trial data to identify low-value assessments and recommend protocol simplification under expert review | 25% reduction in protocol complexity; 30–40% fewer amendments; 15–20% lower participant burden |
| Slow interim analysis cycles delaying adaptive decisions critical to trial success | Supervised automated pipelines generate statistical outputs, survival curves, and interim computations with defined validation checkpoints | 85–90% faster interim analysis turnaround (weeks to days); 2–3× faster decision cycles |
| Growing data volumes from diverse sources overwhelming manual analysis capacity | Integrated execution layer aggregating and analyzing eCRF, lab, device, and genomic data streams under audit-traceable governance | Teams regain 20–30% analytical capacity for high-value modeling and adaptive design work |
All You Need to Know
It continuously analyzes trial design and execution data, identifying protocol inefficiencies and signal trends faster than manual review cycles.
Yes. The AI Workforce analyzes historical data to identify redundant endpoints and recommend simplifications under expert oversight.
Supervised automated pipelines reduce interim analysis turnaround from weeks to days, with full audit traceability.
Analytics tools surface what happened. Maxis AI executes the follow-up - protocol recommendations, data flagging, analysis generation under governance controls.
Yes. By identifying low-value endpoints and complexity risks early, teams have seen 30–40% fewer mid-study amendments.
Looking for Agentic AI for clinical trials?
Explore our Agentic AI Platform to see how AI agents are transforming study startup, data management, oversight, and regulatory submissions.